

## Prevalence and factors associated with not receiving the booster dose of the COVID-19 vaccine in adults in Latin America and the Caribbean

Diego Urrunaga-Pastor<sup>a,b</sup>, Daniel Fernandez-Guzman<sup>c,d</sup>, Brenda Caira-Chuquineyra<sup>c,e</sup>, Percy Herrera-Añazco<sup>b,f,g</sup>, Vicente A. Benites-Zapata<sup>f,h,\*</sup>, Guido Bendezu-Quispe<sup>f,i</sup>

<sup>a</sup> Universidad Científica del Sur, Lima, Peru

<sup>b</sup> Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud, Lima, Peru

<sup>c</sup> Grupo Peruano de Investigación Epidemiológica, Unidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola, Lima, Peru

<sup>d</sup> Escuela Profesional de Medicina Humana, Universidad Nacional de San Antonio Abad del Cusco, Cusco, Peru

<sup>e</sup> Facultad de Medicina, Universidad Nacional de San Agustín, Arequipa, Peru

<sup>f</sup> Red Internacional en Salud Colectiva y Salud Intercultural, Mexico

<sup>g</sup> Universidad Privada San Juan Bautista, Lima, Peru

<sup>h</sup> Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola (USIL), Lima, Peru

<sup>i</sup> Universidad Privada Norbert Wiener, Centro de Investigación Epidemiológica en Salud Global, Lima, Peru

### ARTICLE INFO

#### Keywords:

COVID-19  
SARS-CoV-2  
COVID-19 vaccines  
Vaccination refusal  
COVID-19 vaccine booster shot  
Latin America (source: MeSH)

### ABSTRACT

**Background:** Booster doses have been described as effective in reducing hospitalizations and deaths from the new variants. However, its coverage is heterogeneous in Latin America and the Caribbean (LAC), one of the regions most affected by the pandemic. We aimed to assess the factors associated with not receiving a coronavirus disease 2019 (COVID-19) vaccine booster dose in adults from LAC.

**Methods:** We analyzed a secondary database compiled by the University of Maryland and Facebook assessing the global impact of COVID-19. We included Facebook users over 18 years of age who resided in LAC and responded to the survey between February 13, 2022, and March 14, 2022. We evaluated sociodemographic characteristics, comorbidities, food, and economic insecurity, mental health, and vaccination-related practices. We calculated crude (cPR) and adjusted (aPR) prevalence ratios with their respective 95% confidence intervals (95%CI).

**Results:** The sample included 154,841 adults from 20 LAC countries. 33.7% (n = 46,459) reported not receiving the COVID-19 booster vaccine. Being under 75 years old, having a college, high school, pre-university, primary, or lower education, having no or 1 to 2 comorbidities, living in a town, having food insecurity, depressive symptoms, and having had COVID-19, were associated with a higher prevalence of not receiving the booster dose. In contrast, being female or non-binary and having anxiety symptoms were associated with a lower prevalence of not receiving the booster dose.

**Conclusions:** Approximately three out of 10 adults surveyed in LAC reported not having received the booster vaccine. Authorities must design campaigns that promote receiving a booster dose considering the factors found.

### 1. Introduction

In the scenario of the coronavirus disease 2019 (COVID-19) pandemic, vaccines constitute the most cost-effective strategy to reduce infections, hospitalizations, and deaths in patients infected with SARS-CoV-2 [1,2]. According to the World Health Organization (WHO), by the beginning of April 2022, more than 11 billion doses of vaccines against COVID-19 had been administered worldwide, with more than

five billion people having received at least one dose and more than 4.4 billion people having had two doses [3]. However, despite these efforts, regions such as Africa have reported fewer than 20 doses administered per 100 people [3]. These data have important consequences for global public health, such as the emergence of new variants of the virus with greater transmission capacity [4–6].

Follow-up studies in patients vaccinated against COVID-19 showed a decrease in antibody production, which, together with the appearance

\* Corresponding author. Avenida La Fontana 750, La Molina, Lima, Peru.

E-mail address: [vbeniteszapata@gmail.com](mailto:vbeniteszapata@gmail.com) (V.A. Benites-Zapata).

<https://doi.org/10.1016/j.tmaid.2022.102409>

Received 28 April 2022; Received in revised form 18 July 2022; Accepted 25 July 2022

Available online 9 August 2022

1477-8939/© 2022 Published by Elsevier Ltd.

of new variants, raised the need for booster doses in patients who completed the initial two doses of the vaccine against SARS-CoV-2 [6–8]. Given this, various countries have been providing booster doses against COVID-19. Booster doses have been shown to be effective in reducing hospitalizations and deaths from the new variants, as well as being cost-effective in some health systems, which is why several countries have incorporated boosters into their vaccination schedules [7,9,10]. However, as with the initial doses, the vaccination intent of the booster dose is not universal [11,12]. Studies in Poland, Jordan, China, Denmark, Italy, and Singapore showed that between 44.6% and 95.5% of the general population intend to receive a booster dose [13–19]. This intention is influenced by aspects such as confidence in vaccines, fear of side effects, history of chronic diseases, gender, age or level of education of the people [13–18].

Latin America and the Caribbean (LAC) is one of the regions most affected by the pandemic, with the intention to vaccinate against COVID-19 with the first schedule being 80% in adults and 92.2% in the case of vaccination in children [11,12]. As in the rest of the world, the coverage of the booster dose is heterogeneous and at the beginning of April 2022 varied from 70.43 per 100 people in Chile, 41.46 per 100 in Argentina or 36.57 per 100 in Peru, to coverage as low as 18.57 per 100 in Honduras or 10.27 per 100 in Bolivia [20]. Considering the benefits of a booster dose for public health, knowledge of the factors associated with not having applied the vaccine booster would be useful to improve the design of strategies that seek to increase the proportion of people who have received a booster dose against COVID-19. Although the intention to receive a booster dose has been studied, these studies did not include LAC countries [13–19] and to the best of our knowledge, the associated factors have not been studied in a population that has already received this dose. Therefore, the objective of this research was to study the factors associated with not receiving a booster dose of the COVID-19 vaccine in adults in LAC.

## 2. Methods

### 2.1. Study design

We conducted an analytical cross-sectional study based on data collected by the University of Maryland and Facebook (Facebook, Inc., Menlo Park, CA, USA) on the global trend and impact of COVID-19. Both institutions designed a survey available online through Facebook to assess sociodemographic characteristics, comorbidities, mental health, economic and food insecurity, compliance with mitigation strategies against COVID-19, and practices related to vaccination against this disease.

### 2.2. Population, sample, and sampling

The study population consisted of Facebook users over 18 years of age. We included in the analysis users who resided in LAC and who responded to the survey between February 13, 2022, and March 14, 2022. We excluded participants who did not respond to the dependent variable (self-reported having received at least one booster dose of any COVID-19 vaccine) or that they did not know if the dose they received was a booster. In addition, we excluded responses that had incomplete data on the variables of interest. Likewise, we excluded participants from Haiti because the booster dose vaccination process had not yet started during the period of time analyzed. Thus, we analyzed 154,841 adults from LAC (Fig. 1).

The sampling frame for the random selection of participants included all Facebook users over 18 years of age from a region and country. The survey authors conducted stratified random sampling using administrative boundaries within countries or territories to provide geographic coverage. The selection of the surveyed participants was random based on the sampling frame, which was recalculated daily, and included participants who are Facebook users with similar characteristics throughout each day. If a Facebook user refused to participate, another was randomly invited within the sampling frame. Participants could only take the survey once over an eight-week period.

### 2.3. Questionnaire

The survey used was available from April 23, 2020, in more than 200 countries and in the main language of the territory. The latest version of the survey (version 13, updated on January 30, 2022) consisted of eight sections: 1) The first section included five questions about symptoms related to COVID-19; 2) The second section included three questions about performing diagnostic tests for COVID-19; 3) The third section included 18 questions related to vaccination against COVID-19; 4) The fourth section included six questions related to sociodemographic data; 5) The fifth section included four questions on behaviors related to COVID-19; 6) The sixth section included information about the perception, prevention practices and sources of information against COVID-19; 7) The seventh section included questions related to health conditions and aspects related to children; and 8) The eighth section included two questions about the participant's occupation. This survey has been used to develop previous studies [11,12,21–23], and the survey methodology has been described in greater detail previously [24].




Fig. 1. Flowchart of the selection of the study sample.

## 2.4. Variables

### 2.4.1. Outcome variable: not receiving a COVID-19 booster dose

We assessed whether adults had not received a booster dose of the COVID-19 vaccine using the following survey question: Have you received an additional dose or booster shot of the COVID-19 vaccine? This question had four possible alternatives: yes, I received an additional dose or booster; yes, I received 2 or more additional doses or booster shots; no, I have not received an additional dose or booster shot; and I don't know. Subsequently, we dichotomized the variable considering the first two alternatives as having received the booster dose against COVID-19, while the third was considered as not having received a booster dose. We excluded participants who answered the fourth option.

### 2.5. Independent variables

**Sociodemographic variables:** We included the following sociodemographic variables (the categories considered for these variables in the study are described in parentheses): gender (male, female and non-binary), age (18–24, 25–34, 35–44, 45–54, 55–64, 65–74 or greater than or equal to 75 years), area of residence (city, town or village/rural area), educational level (completed primary school/less than primary school/no formal education, school complete secondary/pre-university/high school (or equivalent), complete university or postgraduate), employment (yes or no).

**Comorbidities, personal history, and history of COVID-19:** Participants reported the following comorbidities: asthma, chronic obstructive pulmonary disease or chronic bronchitis or emphysema, cancer, diabetes mellitus, high blood pressure, kidney disease, compromised or weakened immune system, heart attack or other heart disease and obesity. We generated a variable that grouped comorbidities as: none, one to two, and greater than or equal to three. We also included self-reporting of having had COVID-19 (yes or no).

**Food and economic insecurity:** We assessed food insecurity with the following survey question: How worried are you about having enough to eat in the next week? This question had four possible answers: very worried, somewhat worried, not too worried, and not worried at all. We considered the first three responses as food insecurity. On the other hand, we defined economic insecurity using the following question: How worried are you about your household's finances in the next month? It had four possible answers: very worried, somewhat worried, not too worried, and not worried at all. We defined economic insecurity using the first three answers.

**Anxiety and depression symptoms:** We assessed anxiety symptoms using the question: During the last 7 days, how often did you feel so nervous that nothing could calm you down? This question is part of the Kessler Psychological Distress Scale (K10), and the survey had 5 possible answers: all the time, most of the time, some of the time, a little of the time and none of the time. Therefore, we dichotomized the variable considering the first three alternatives as the presence of anxiety symptoms. We assessed depressive symptoms using the following survey question: How often did you feel so depressed in the past 7 days that nothing could cheer you up? This question is part of the K10, and the survey had five possible answers: all the time, most of the time, some of the time, a little of the time and none of the time. Therefore, we dichotomized the variable considering the first four alternatives as the presence of depressive symptoms.

### 2.6. Statistical analysis

We downloaded the database in Microsoft Excel 2019 ® format for each day within the study period, then imported and merged the data in the Stata/SE ® version 17.0 statistical software (StataCorp, College Station, TX, USA). Finally, we performed the statistical analysis considering the complex sampling of the survey and the svy command.

We estimated weighted proportions with their respective 95%

confidence intervals (95%CI) and absolute frequencies to describe the characteristics of the participants. We used the Chi-square test with Rao-Scott correction to perform the bivariate analysis between the independent variables and not having received a COVID-19 booster dose. We used two generalized linear models (crude and adjusted) of the Poisson family with logarithmic link function to estimate the factors associated with not having received a booster dose against COVID-19. We estimated crude (cPR) and adjusted (aPR) prevalence ratios with their respective 95%CI. We used a statistical criterion for the adjusted regression model (variables with a p value < 0.05 were included in the crude model). We evaluated the possible collinearity of the associated factors included in the final adjusted model.

### 2.7. Ethical issues

This study did not require the approval of an ethics committee since we analyzed a secondary database. This database collected data without identifiers, which ensures the protection of the confidentiality of the survey participants. Respondents gave informed consent prior to completing the survey. Access to the survey database was obtained with permission from the University of Maryland.

## 3. Results

### 3.1. Characteristics of the study sample

We analyzed a sample of 154,841 adults from 20 LAC countries. We found that 51.7% (n = 87,754) were women, 21.7% (n = 33,635) were between 25 and 34 years old, 42.4% (n = 60,213) had a secondary or pre-university education, 82.2% (n = 130,740) lived in a city; 59.8% (n = 89,117) reported food insecurity, and 78.8% (n = 121,046) reported economic insecurity. Additionally, 39.2% (n = 62,341) and 44.3% (n = 68,891) reported having anxious and depressive symptoms, respectively; 56.4% (n = 83,717) reported having no comorbidities, 43.9% (n = 68,203) had had COVID-19 at some point, and 33.7% (n = 46,459) reported not having received a COVID-19 booster vaccine (Table 1). The countries with the highest prevalence of not receiving a booster dose were Venezuela (66.6%) and Bolivia (49.5%), while the Latin American countries with the highest prevalence of receiving a booster dose were Chile (92.6%) and Uruguay (88.1%) (Fig. 2 and Supplementary Material).

### 3.2. Bivariate analysis according to not having received the booster vaccine against COVID-19

We found statistically significant differences in the bivariate analysis between the independent variables and not having received the COVID-19 booster vaccine, except for being employed (p = 0.345) (Table 2).

### 3.3. Factors associated with not having received the booster vaccine against COVID-19

The adjusted statistical regression model showed a higher prevalence of not having received the COVID-19 booster vaccine among people aged 65–74 years (aPR = 1.23; 95%CI: 1.02–1.48; p = 0.029), 55–64 years old (aPR = 1.82; 95%CI: 1.49–2.22; p < 0.001), 45–54 years old (aPR = 2.33; 95%CI: 1.88–2.89; p < 0.001), 35–44 years old (aPR = 3.06; 95%CI: 2.44–3.84; p < 0.001), 25–34 years old (aPR = 3.95; 95%CI: 3.12–5.01; p < 0.001) and 18–24 years old (aPR = 4.86; 95%CI: 3.81–6.20; p < 0.001) compared to those aged 75 and over. We found a lower prevalence of not having received the booster vaccine in female (aPR = 0.89; 95%CI: 0.87–0.92; p < 0.001) and non-binary participants (aPR = 0.76; 95%CI: 0.60–0.97; p = 0.025) compared to the male gender group. Compared with having a postgraduate educational level, having a university (aPR = 1.27; 95%CI: 1.21–1.32; p < 0.001), secondary or pre-university education (aPR = 1.39; 95%CI: 1.32–1.47; p <

**Table 1**  
Characteristics of the study population (n = 154,841).

| Characteristics                   | n       | % <sup>a</sup> | 95%CI <sup>a</sup> |
|-----------------------------------|---------|----------------|--------------------|
| <b>Gender</b>                     |         |                |                    |
| Male                              | 66,827  | 48.1           | 47.4–48.9          |
| Female                            | 87,754  | 51.7           | 50.9–52.4          |
| Non-binary                        | 260     | 0.2            | 0.17–0.23          |
| <b>Age (years)</b>                |         |                |                    |
| 18 - 24                           | 17,636  | 15.4           | 14.7–16.2          |
| 25 - 34                           | 33,635  | 21.7           | 21.1–22.3          |
| 35 - 44                           | 35,110  | 20.1           | 19.8–20.4          |
| 45 - 54                           | 30,628  | 18.9           | 18.6–19.2          |
| 55 - 64                           | 24,552  | 12.6           | 12.1–13.2          |
| 65 - 74                           | 11,095  | 9.5            | 9.0–10.2           |
| 75 years or older                 | 2,185   | 1.7            | 1.5–1.9            |
| <b>Area of residence</b>          |         |                |                    |
| City                              | 130,740 | 82.2           | 79.0–85.1          |
| Town                              | 14,839  | 11.3           | 9.1–13.9           |
| Village or rural area             | 9,262   | 6.5            | 5.6–7.4            |
| <b>Educational level</b>          |         |                |                    |
| Primary school or less            | 12,384  | 8.8            | 7.6–10.2           |
| Secondary school – pre-university | 60,213  | 42.4           | 41.2–43.7          |
| University                        | 58,541  | 35.6           | 33.9–37.3          |
| Postgraduate                      | 23,703  | 13.2           | 12.2–14.2          |
| <b>Employment</b>                 |         |                |                    |
| No                                | 61,475  | 42.3           | 41.0–43.6          |
| Yes                               | 93,366  | 57.7           | 56.4–59.0          |
| <b>Comorbidities</b>              |         |                |                    |
| None                              | 83,717  | 56.4           | 55.3–57.4          |
| 1 to 2                            | 62,811  | 38.7           | 38.0–39.5          |
| Greater than or equal to 3        | 8,313   | 4.9            | 4.5–5.3            |
| <b>History of COVID-19</b>        |         |                |                    |
| No                                | 86,638  | 56.1           | 54.7–57.4          |
| Yes                               | 68,203  | 43.9           | 42.6–45.3          |
| <b>Food insecurity</b>            |         |                |                    |
| No                                | 65,664  | 40.2           | 38.8–41.5          |
| Yes                               | 89,117  | 59.8           | 58.5–61.2          |
| <b>Economic insecurity</b>        |         |                |                    |
| No                                | 33,795  | 21.2           | 20.6–21.9          |
| Yes                               | 121,046 | 78.8           | 78.1–79.4          |
| <b>Anxiety symptoms</b>           |         |                |                    |
| No                                | 92,500  | 60.8           | 59.9–61.6          |
| Yes                               | 62,341  | 39.2           | 38.4–40.1          |
| <b>Depressive symptoms</b>        |         |                |                    |
| No                                | 85,950  | 55.7           | 55.0–56.5          |
| Yes                               | 68,891  | 44.3           | 43.5–45.0          |
| <b>Having received a booster</b>  |         |                |                    |
| Yes                               | 108,382 | 66.3           | 63.7–68.7          |
| No                                | 46,459  | 33.7           | 31.3–36.3          |

95%CI: 95% confidence intervals.

<sup>a</sup> Weighted percentages according to survey complex sampling.

0.001) or having a primary level or less (aPR = 1.31; 95%CI: 1.22–1.40;  $p < 0.001$ ) was associated with a higher prevalence of not having received the booster vaccine. In addition, compared to having three or more comorbidities, having one to two comorbidities (aPR = 1.09; 95% CI: 1.03–1.16;  $p = 0.003$ ) or not having any comorbidities (aPR = 1.21; 95%CI: 1.13–1.29;  $p < 0.001$ ) was associated with a higher prevalence of not having received the COVID-19 booster vaccine. Likewise, living in a town (aPR = 1.09; 95%CI: 1.02–1.17;  $p = 0.012$ ), having food insecurity (aPR = 1.10; 95%CI: 1.07–1.14;  $p < 0.001$ ), depressive symptoms (aPR = 1.06; 95%CI: 1.04–1.09;  $p < 0.001$ ) and having had COVID-19 (aPR = 1.24; 95%CI: 1.20–1.28;  $p < 0.001$ ) were associated with a higher prevalence of not having received the booster vaccine. On the other hand, having symptoms of anxiety (aPR = 0.95; 95%CI: 0.92–0.98;  $p < 0.001$ ) was associated with a lower prevalence of not having received the COVID-19 booster vaccine (Table 3).

## 4. Discussion

### 4.1. Main findings

This study aimed to assess the prevalence and factors associated with

not receiving a booster dose of the COVID-19 vaccine. Our findings show that approximately one in three participants did not receive a booster dose. Being under the age of 75, having a college, high school or pre-university, and primary education or less, having no or fewer than three comorbidities, living in a town, being food insecure, having depressive symptoms, and having had COVID-19, were associated with a higher prevalence of not having received the booster dose. In contrast, being female or non-binary and having anxiety symptoms were associated with a lower prevalence of not having received the booster dose.

### 4.2. Prevalence of not having received a booster dose in LAC countries

As of March 27, 2022, 81.6% of the Chilean population and 62.9% of the Uruguayan population had received a booster dose [20]. On the other hand, the WHO reported that for that date, 2.3% and 9.9% of the population received a booster dose in Venezuela and Bolivia, respectively [3]. Although Chile and Uruguay lead the coverage of the booster dose [3], the difference in the percentages of the population receiving the booster vaccination in the present study could be due to the type of sample used in our research. While our study included the population that accessed a social network, the WHO reports include official data collected by governments [3].

The heterogeneity of booster dose coverage across countries is multifactorial and includes structural aspects of vaccination strategies [25]. However, differences in booster vaccination coverage among countries may also be explained by individual aspects regarding the perception of the booster dose. In Poland, the main reasons for not accepting the booster dose were side effects experienced after previous doses, the opinion that it is unnecessary, and uncertainty regarding its safety [13]. In Jordan, there were doubts about its usefulness, because according to the perception of the interviewees, the previous doses had been received a short time ago or that, with a history of infection, an additional dose was not necessary [14]. In China, confidence in the effectiveness of COVID-19 vaccines against SARS-CoV-2 and its variants and having previously received the vaccine influenced the need for a booster dose [16]. Although our study does not identify the reasons for the intention to receive a booster dose, it is clear that it is necessary to encourage the population to receive the booster vaccine, since in some LAC countries, the campaign for a fourth dose is already being reinforced [26,27]. In this sense, identifying the population groups or the characteristics of the population in which this dose is more or less accepted will allow the countries to individualize these campaigns.

### 4.3. Factors associated with not receiving a booster dose

Compared with persons under 75 years of age, all participants in lower age ranges had a lower probability of having received a booster dose, with the probability being lower when the respondent was younger. Similarly, compared with individuals with more than three comorbidities, those who had less than two or none were less likely to receive a booster dose. This is because most countries prioritized this dose in the population at risk; that is, the older adult population or those with more comorbidities [28,29]. However, it is likely that the perceived health of older adults also influences the likelihood of receiving a booster dose. In Poland, older adults who perceived better health status after the initial vaccination schedule were more likely to receive a booster dose [13].

Our results show that in people with anxiety symptoms there was a lower prevalence of not having received the booster dose. These results are similar to the intention of parents with symptoms of anxiety in LAC to vaccinate children and adolescents against COVID-19 in association with fear of the consequences that the infection may cause in their children [12]. In the same context, in adults, the fear of becoming ill or that a relative becomes seriously ill, was also associated with a greater probability of vaccination intention [11]. Although they are not comparable situations since our study did not evaluate the intention to be




Fig. 2. Prevalence of not having received a COVID-19 vaccine booster in Latin America and the Caribbean countries.

vaccinated against COVID-19, but rather having received a booster dose, these results suggest that fear of the disease and its consequences still play an important role in the decision of some people to be vaccinated with a booster dose. In Denmark, vaccination intention was less frequent in groups that do not see COVID-19 as a threat to society [17]. In Italy, the intention to receive a booster dose was higher in those who had had a relative diagnosed with the disease [18], and in China, the same was true in the population that had a higher perception of susceptibility [15]. In people with anxiety, there is probably a greater intention to comply with the measures to prevent the disease due to the anxiety condition, which could explain their greater intention to receive the vaccine [30], even describing a greater intention to pay to receive the vaccine [31]. The aforementioned could explain a greater probability of receiving a booster vaccine in people with anxiety.

Our results showed that some conditions that were previously associated with a higher vaccination intention in LAC were associated with a higher prevalence of not having received the booster dose, such as having food insecurity, depressive symptoms, and having had COVID-19 [11,12]. These results could be explained by the indirect effects of a prolonged pandemic. This study was carried out when the countries were coming out of a wave of infection by the omicron variant of SARS-CoV-2, in which there was a lower number of deaths due to either less severity of the clinical symptoms or an increase in coverage of two doses worldwide [3,29]. This could give the impression that further measures against the pandemic are not necessary, since in parallel to this, many Latin American countries lifted some restriction measures [32]. In the case of people with depression, it is described that they are more likely to endorse false statements about COVID-19 and have half the likely to be vaccinated compared with those without depression, being proposed that a lack of positive interpretation bias or optimistic beliefs could conditionate those results mentioned above [33]. Additionally, there has been physical and mental exhaustion due to the restrictions related to the pandemic called “pandemic fatigue”, which causes people to decrease adherence to measures to prevent infection compared to the start of the pandemic [34,35].

As in the case of vaccination intention in children and adolescents, having a lower educational level was associated with not receiving a booster dose [13]. Likewise, although the two studies are not

comparable because we did not evaluate vaccination intention, in China, a low educational level and low knowledge about COVID-19 were associated with a lower intention to receive the booster dose [15]. Our results may also be related to the infodemic which affects vaccination campaigns and impacts people regardless of educational level by the dissemination of erroneous information regarding vaccines [36,37]. This is relevant, because the intention to receive an additional dose is related to aspects such as doubts regarding the need, usefulness and safety of the booster. In this sense, in Denmark, individuals who did not perceive the advice of the health authorities as effective against the spread of the disease had lower acceptance of the booster dose [17].

Being female or non-binary was associated with a higher probability of having a booster dose, unlike previous studies reporting that the intention of receiving booster vaccination was greater in men in both the LAC region and worldwide [11,38]. While it has been described that women are more exposed to anti-vaccine groups and that men are less susceptible to disease-related conspiracy theories [39–41], in the present study population this did not seem to influence the decision to receive the booster dose. Throughout the world, the participation of women in the fight against the pandemic has been important, with their collaboration with institutions performing effective and inclusive responses to COVID-19, from the highest decision-making levels to the provision of front-line services [6,42], thereby favoring the empowerment of women in health decision making. Although it has been described that “pandemic fatigue” affects women more than men [43], there are differences in both mental health problems and adherence to some community mitigation measures [21,22], a situation which has also been described in the non-binary population [44]. However, while these aspects were not evaluated in this study, they could influence the findings, and thus, more studies are required regarding the influence of gender on the decision to receive a COVID-19 booster dose.

#### 4.4. Strengths and limitations

Our study has some limitations. First, because the respondents were users of a social network, information was only obtained from people with access to the internet and social networks, which could vary between the regions of the countries evaluated or the rural populations.

**Table 2**  
Prevalence of not having received booster according to the characteristics of the study population.

| Characteristics                   | Not having received booster |                |                    |        |                |                    | P value <sup>b</sup> |
|-----------------------------------|-----------------------------|----------------|--------------------|--------|----------------|--------------------|----------------------|
|                                   | Yes                         |                |                    | No     |                |                    |                      |
|                                   | n                           | % <sup>a</sup> | 95%CI <sup>a</sup> | n      | % <sup>a</sup> | 95%CI <sup>a</sup> |                      |
| <b>Gender</b>                     |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| Male                              | 45,725                      | 64.3           | 61.9–66.6          | 21,102 | 35.7           | 33.4–38.1          |                      |
| Female                            | 62,486                      | 68.1           | 65.4–70.7          | 25,268 | 31.9           | 29.3–34.6          |                      |
| Non-binary                        | 171                         | 65.5           | 56.3–73.7          | 89     | 34.5           | 26.3–43.7          |                      |
| <b>Age (years)</b>                |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| 18–24                             | 7,704                       | 42.6           | 39.9–45.5          | 9,932  | 57.4           | 54.5–60.2          |                      |
| 25–34                             | 19,735                      | 55.3           | 52.1–58.4          | 13,900 | 44.7           | 41.6–47.9          |                      |
| 35–44                             | 24,497                      | 66.2           | 63.7–68.4          | 10,613 | 33.8           | 31.4–36.3          |                      |
| 45–54                             | 23,966                      | 75.0           | 72.7–77.3          | 6,662  | 25.0           | 22.7–27.3          |                      |
| 55–64                             | 20,592                      | 81.2           | 79.1–83.2          | 3,960  | 18.8           | 16.8–20.9          |                      |
| 65–74                             | 9,989                       | 87.9           | 85.8–89.8          | 1,202  | 12.1           | 10.2–14.2          |                      |
| 75 years or older                 | 1,995                       | 90.5           | 87.7–92.7          | 190    | 9.5            | 7.3–12.3           |                      |
| <b>Area of residence</b>          |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| City                              | 92,194                      | 67.2           | 64.5–69.8          | 38,546 | 32.8           | 30.2–35.5          |                      |
| Town                              | 9,709                       | 60.5           | 58.2–62.8          | 5,130  | 39.5           | 37.2–41.8          |                      |
| Village or rural area             | 6,479                       | 64.2           | 61.9–66.4          | 2,783  | 35.8           | 33.6–38.1          |                      |
| <b>Educational level</b>          |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| Primary school or less            | 8,872                       | 69.0           | 66.3–71.7          | 3,512  | 31.0           | 28.3–33.7          |                      |
| Secondary school – pre-university | 39,245                      | 61.1           | 58.6–63.6          | 20,968 | 38.9           | 36.4–41.4          |                      |
| University                        | 41,111                      | 67.0           | 64.1–69.8          | 17,430 | 33.3           | 30.2–35.9          |                      |
| Postgraduate                      | 19,154                      | 79.0           | 76.9–81.0          | 4,549  | 21.0           | 19.0–23.1          |                      |
| <b>Employment</b>                 |                             |                |                    |        |                |                    | 0.345                |
| No                                | 43,123                      | 66.6           | 64.0–69.1          | 18,352 | 33.4           | 30.9–36.0          |                      |
| Yes                               | 65,259                      | 66.0           | 63.4–68.5          | 28,107 | 34.0           | 31.5–36.6          |                      |
| <b>Comorbidities</b>              |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| None                              | 55,049                      | 61.8           | 59.3–64.3          | 28,668 | 38.2           | 35.7–40.7          |                      |
| 1 to 2                            | 46,588                      | 71.3           | 68.8–73.6          | 16,223 | 28.7           | 26.4–31.2          |                      |
| Greater than or equal to 3        | 6,745                       | 77.8           | 74.9–80.3          | 1,568  | 22.2           | 19.7–25.1          |                      |
| <b>History of COVID-19</b>        |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| No                                | 64,702                      | 70.4           | 67.8–72.9          | 21,936 | 29.6           | 27.1–32.2          |                      |
| Yes                               | 43,680                      | 61.0           | 58.6–63.4          | 24,523 | 39.0           | 36.6–41.4          |                      |
| <b>Food insecurity</b>            |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| No                                | 48,569                      | 71.0           | 68.6–73.2          | 17,095 | 29.0           | 26.8–31.4          |                      |
| Yes                               | 59,813                      | 63.1           | 60.5–65.6          | 29,364 | 36.9           | 34.4–39.5          |                      |
| <b>Economic insecurity</b>        |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| No                                | 25,663                      | 72.9           | 70.6–75.0          | 8,132  | 27.1           | 25.0–29.4          |                      |
| Yes                               | 82,719                      | 64.5           | 61.8–67.1          | 38,327 | 35.5           | 32.9–38.2          |                      |
| <b>Anxiety symptoms</b>           |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| No                                | 66,516                      | 68.2           | 65.7–70.6          | 25,984 | 31.8           | 29.4–34.3          |                      |
| Yes                               | 41,866                      | 63.2           | 60.4–65.9          | 20,475 | 36.8           | 34.1–39.6          |                      |
| <b>Depressive symptoms</b>        |                             |                |                    |        |                |                    | <b>&lt;0.001</b>     |
| No                                | 63,011                      | 70.0           | 67.7–72.2          | 22,939 | 30.0           | 27.8–32.3          |                      |
| Yes                               | 45,371                      | 61.6           | 58.6–64.5          | 23,520 | 38.4           | 35.5–41.4          |                      |

95%CI: 95% confidence interval.

P-values <0.05 are in bold.

<sup>a</sup> Weighted percentages according to survey complex sampling.

<sup>b</sup> Calculated by Chi2 test of independence with Rao Scott correction for complex sampling.

Then, this could overestimate the prevalence's found in this study. Second, the variables included, and their definition are subject to the pre-established definition of the parent survey and there could be relevant variables not included in our analysis. Third, the data was obtained by self-reporting, and thus, there may be underreporting of information. Fourth, causality among the variables evaluated cannot be established due to the cross-sectional design of the study. Fifth, the measurements used to assess food and economic security were not validated, however, they provide relevant information to the study. Sixth, we do not have the frequency of non-response, which is relevant in the context of an online survey, and this may induce bias to our results due to the frequency of user rejection in the survey, as well as the possibility of occurrence of voluntary response bias. Despite these limitations, the sample size was large with national representation in various countries of the continent that can help understand the study subject.

## 5. Conclusions

In conclusion, one in three participants did not receive a booster

dose. The countries with the highest prevalence of not having received a booster dose were Venezuela and Bolivia. Being under 75 years of age, having the lowest level of education, having fewer than three comorbidities, living in a town, having food insecurity, depressive symptoms, and having had COVID-19 were associated with a higher prevalence of not having received the booster dose. In contrast, being female or non-binary and having anxiety symptoms were associated with a lower prevalence of not having received the booster dose. The results of this study suggest the need to develop booster vaccination campaigns with a greater focus on gender and to prioritize messages and content according to population subgroups to increase the receipt of booster doses.

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Table 3**  
Factors associated with not having received a booster in adults from Latin America and the Caribbean.

| Characteristics                   | Crude model |           |                  | Adjusted model            |           |                  |
|-----------------------------------|-------------|-----------|------------------|---------------------------|-----------|------------------|
|                                   | cPR         | 95%CI     | P value          | aPR                       | 95%CI     | P value          |
| <b>Gender</b>                     |             |           |                  |                           |           |                  |
| Male                              | Ref.        |           |                  | Ref.                      |           |                  |
| Female                            | 0.89        | 0.87–0.92 | <b>&lt;0.001</b> | 0.89                      | 0.87–0.92 | <b>&lt;0.001</b> |
| Non-binary                        | 0.97        | 0.76–1.22 | 0.768            | 0.76                      | 0.60–0.97 | <b>0.025</b>     |
| <b>Age (years)</b>                |             |           |                  |                           |           |                  |
| 75 years or older                 | Ref.        |           |                  | Ref.                      |           |                  |
| 65–74                             | 1.28        | 1.05–1.53 | <b>0.014</b>     | 1.23                      | 1.02–1.48 | <b>0.029</b>     |
| 55–64                             | 1.97        | 1.61–2.41 | <b>&lt;0.001</b> | 1.82                      | 1.49–2.22 | <b>&lt;0.001</b> |
| 45–54                             | 2.62        | 2.11–3.25 | <b>&lt;0.001</b> | 2.33                      | 1.88–2.89 | <b>&lt;0.001</b> |
| 35–44                             | 3.55        | 2.82–4.46 | <b>&lt;0.001</b> | 3.06                      | 2.44–3.84 | <b>&lt;0.001</b> |
| 25–34                             | 4.70        | 3.71–5.96 | <b>&lt;0.001</b> | 3.95                      | 3.12–5.01 | <b>&lt;0.001</b> |
| 18–24                             | 6.03        | 4.70–7.72 | <b>&lt;0.001</b> | 4.86                      | 3.81–6.20 | <b>&lt;0.001</b> |
| <b>Area of residence</b>          |             |           |                  |                           |           |                  |
| City                              | Ref.        |           |                  | Ref.                      |           |                  |
| Town                              | 1.20        | 1.12–1.30 | <b>&lt;0.001</b> | 1.09                      | 1.02–1.17 | <b>0.012</b>     |
| Village or rural area             | 1.09        | 1.02–1.17 | <b>0.008</b>     | 1.02                      | 0.96–1.08 | 0.572            |
| <b>Educational level</b>          |             |           |                  |                           |           |                  |
| Postgraduate                      | Ref.        |           |                  | Ref.                      |           |                  |
| University                        | 1.57        | 1.50–1.65 | <b>&lt;0.001</b> | 1.27                      | 1.21–1.32 | <b>&lt;0.001</b> |
| Secondary school – pre-university | 1.85        | 1.75–1.96 | <b>&lt;0.001</b> | 1.39                      | 1.32–1.47 | <b>&lt;0.001</b> |
| Primary school or less            | 1.48        | 1.37–1.58 | <b>&lt;0.001</b> | 1.31                      | 1.22–1.40 | <b>&lt;0.001</b> |
| <b>Employment</b>                 |             |           |                  |                           |           |                  |
| Yes                               | Ref.        |           |                  | Not included <sup>a</sup> |           |                  |
| No                                | 0.98        | 0.95–1.01 | 0.251            |                           |           |                  |
| <b>Comorbidities</b>              |             |           |                  |                           |           |                  |
| Greater than or equal to 3        | Ref.        |           |                  | Ref.                      |           |                  |
| 1 to 2                            | 1.29        | 1.21–1.38 | <b>&lt;0.001</b> | 1.09                      | 1.03–1.16 | <b>0.003</b>     |
| None                              | 1.72        | 1.59–1.85 | <b>&lt;0.001</b> | 1.21                      | 1.13–1.29 | <b>&lt;0.001</b> |
| <b>History of COVID-19</b>        |             |           |                  |                           |           |                  |
| No                                | Ref.        |           |                  | Ref.                      |           |                  |
| Yes                               | 1.32        | 1.27–1.37 | <b>&lt;0.001</b> | 1.24                      | 1.20–1.28 | <b>&lt;0.001</b> |
| <b>Food insecurity</b>            |             |           |                  |                           |           |                  |
| No                                | Ref.        |           |                  | Ref.                      |           |                  |
| Yes                               | 1.27        | 1.23–1.31 | <b>&lt;0.001</b> | 1.10                      | 1.07–1.14 | <b>&lt;0.001</b> |
| <b>Economic insecurity</b>        |             |           |                  |                           |           |                  |
| No                                | Ref.        |           |                  | Not included <sup>b</sup> |           |                  |
| Yes                               | 1.31        | 1.27–1.35 | <b>&lt;0.001</b> |                           |           |                  |
| <b>Anxiety symptoms</b>           |             |           |                  |                           |           |                  |
| No                                | Ref.        |           |                  | Ref.                      |           |                  |
| Yes                               | 1.16        | 1.12–1.19 | <b>&lt;0.001</b> | 0.95                      | 0.92–0.98 | <b>&lt;0.001</b> |
| <b>Depressive symptoms</b>        |             |           |                  |                           |           |                  |
| No                                | Ref.        |           |                  | Ref.                      |           |                  |
| Yes                               | 1.28        | 1.25–1.31 | <b>&lt;0.001</b> | 1.06                      | 1.04–1.09 | <b>&lt;0.001</b> |

cPR: crude prevalence ratio; aPR: adjusted prevalence ratio; 95%CI: 95% confidence interval.

Prevalence ratios and confidence intervals were calculated taking into account the complex sampling of the survey.

P-values <0.05 are in bold.

<sup>a</sup> Not included due to not having a statistically significant association in the crude model.

<sup>b</sup> Not included due to collinearity with food insecurity.

### Authors' contributions

All authors made substantial contributions to the study's conception and design, analysis, and interpretation.

### Ethical approval

We analyzed a secondary database without identifiers and participants gave informed consent prior to answering the survey. Then, the integrity of the participants was not compromised, and this study is exempt from an institutional review board ethical approval. We obtained the data by signing a research data use agreement with the University of Maryland. We downloaded the data without identifiers.

### CRedit authorship contribution statement

**Diego Urrunaga-Pastor:** Conceptualization, Methodology, Writing – original draft, Writing – review & editing. **Daniel Fernandez-Guzman:** Conceptualization, Methodology, Writing – original draft. **Brenda**

**Caira-Chuquineyra:** Conceptualization, Methodology, Writing – original draft. **Percy Herrera-Añazco:** Conceptualization, Methodology, Writing – original draft, Writing – review & editing. **Vicente A. Benites-Zapata:** Conceptualization, Methodology, Writing – original draft, Writing – review & editing. **Guido Bendezu-Quispe:** Conceptualization, Methodology, Writing – original draft, Writing – review & editing.

### Declaration of competing interest

The authors declare that they have no competing interests.

### Acknowledgements

The authors would like to thank the University of Maryland and Facebook, Inc for conducting and making the survey dataset available. In addition, we thank the Universidad Científica del Sur for English editing support.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tmaid.2022.102409>.

## References

- Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, Asgharzadeh M, Ganbarov K, et al. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review. *Int J Biol Macromol* 2021;188:740–50. <https://doi.org/10.1016/j.ijbiomac.2021.08.076>.
- Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. *Inflammopharmacology* 2021;29:1357–60. <https://doi.org/10.1007/s10787-021-00847-2>.
- World Health Organization. World Health Organization Coronavirus (COVID-19) dashboard [cited 3 jul 2022]. Available at, <https://covid19.who.int/>; 2021.
- Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. *Curr Med Sci* 2021;41:1037–51. <https://doi.org/10.1007/s11596-021-2395-1>.
- Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. *Clin Microbiol Infect* 2021. <https://doi.org/10.1016/j.cmi.2021.10.005>.
- La Organización Panamericana de la Salud (OPS) y la Comisión Económica para América Latina y el Caribe (CEPAL). The prolongation of the health crisis and its impact on health, the economy and social development. CEPAL [cited 3 jul 2022]. Available at, <https://repositorio.cepal.org/handle/11362/47302>; 2021.
- Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, et al. The advisory committee on immunization practices' interim recommendations for additional primary and booster doses of COVID-19 vaccines—United States, 2021. *Morb Mortal Wkly Rep* 2021;70:1545. <https://doi.org/10.15585/mmwr.mm7044e2>.
- Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 2022. [https://doi.org/10.1016/S0140-6736\(22\)00152-0](https://doi.org/10.1016/S0140-6736(22)00152-0).
- Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. *N Engl J Med* 2021;385:1393–400. <https://doi.org/10.1056/NEJMoa2114255>.
- Li R, Liu H, Fairley CK, Zou Z, Xie L, Li X, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. *Int J Infect Dis* 2022. <https://doi.org/10.1016/j.ijid.2022.03.029>.
- Urrunaga-Pastor D, Bendezu-Quispe G, Herrera-Añazco P, Uyen-Cateriano A, Toro-Huamanchumo CJ, Rodríguez-Morales AJ, et al. Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean. *Trav Med Infect Dis* 2021;41:102059. <https://doi.org/10.1016/j.tmaid.2021.102059>.
- Urrunaga-Pastor D, Herrera-Añazco P, Uyen-Cateriano A, Toro-Huamanchumo CJ, Rodríguez-Morales AJ, Hernández AV, et al. Prevalence and factors associated with parents' non-intention to vaccinate their children and adolescents against COVID-19 in Latin America and the Caribbean. *Vaccines* 2021;9:1303. <https://doi.org/10.3390/vaccines9111303>.
- Rzymiski P, Poniedziałek B, Fal A. Willingness to receive the booster COVID-19 vaccine dose in Poland. *Vaccines* 2021;9:1286. <https://doi.org/10.1080/14760584.2022.2016401>.
- Al-Qerem W, Al Bawab AQ, Hammad A, Ling J, Alasmari F. Willingness of the Jordanian population to receive a COVID-19 booster dose: a cross-sectional study. *Vaccines* 2022;10:410. <https://doi.org/10.3390/vaccines10030410>.
- Qin C, Wang R, Tao L, Liu M, Liu J. Acceptance of a third dose of COVID-19 vaccine and associated factors in China based on health belief model: a national cross-sectional study. *Vaccines* 2022;10:89. <https://doi.org/10.3390/vaccines10010089>.
- Tung T-H, Lin X-Q, Chen Y, Zhang M-X, Zhu J-S. Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China. *Expert Rev Vaccines* 2022;21:261–7. <https://doi.org/10.1080/14760584.2022.2016401>.
- Jørgensen FJ, Nielsen LH, Petersen MB. Willingness to take the booster vaccine in a nationally representative sample of Danes. *Vaccines* 2022;10:425. <https://doi.org/10.3390/vaccines10030425>.
- Folcarelli L, Miraglia del Giudice G, Corea F, Angelillo IF. Intention to receive the COVID-19 vaccine booster dose in a university community in Italy. *Vaccines* 2022;10:146. <https://doi.org/10.3390/vaccines10020146>.
- Koh SWC, Tan HM, Lee WH, Mathews J, Young D. COVID-19 vaccine booster hesitancy among healthcare workers: a retrospective observational study in Singapore. *Vaccines* 2022;10:464. <https://doi.org/10.3390/vaccines10030464>.
- Statista. Número de vacunados por cada 100 habitantes y dosis de refuerzo administradas contra el coronavirus (COVID-19) en América Latina y el Caribe a 27 de marzo de 2022, por país 2022. <https://es.statista.com/estadisticas/1282619/dosis-y-pauta-de-tercera-vacunacion-contra-la-covid-19-por-pais-america-latina/>; 2022.
- Herrera-Añazco P, Urrunaga-Pastor D, Benites-Zapata VA, Bendezu-Quispe G, Toro-Huamanchumo CJ, Hernández AV. COVID-19 symptomatology and compliance with community mitigation strategies in Latin America early during the COVID-19 pandemic. *Prev Med Reports* 2022;25:101665. <https://doi.org/10.1016/j.pmedr.2021.101665>.
- Herrera-Añazco P, Urrunaga-Pastor D, Benites-Zapata VA, Bendezu-Quispe G, Toro-Huamanchumo CJ, Hernández AV. Gender differences in depressive and anxiety symptoms during the first stage of COVID-19 pandemic: a cross-sectional study in Latin American and the Caribbean. *Front Psychiatr* 2022;170. <https://doi.org/10.3389/fpsy.2022.727034>.
- Benites-Zapata VA, Urrunaga-Pastor D, Solorzano-Vargas ML, Herrera-Añazco P, Uyen-Cateriano A, Bendezu-Quispe G, et al. Prevalence and factors associated with food insecurity in Latin America and the Caribbean during the first wave of the COVID-19 pandemic. *Heliyon* 2021;7:e08091. <https://doi.org/10.1016/j.heliyon.2021.e08091>.
- Barkay N, Cobb C, Eilat R, Galili T, Haimovich D, LaRocca S, et al. Weights and methodology brief for the COVID-19 symptom survey by University of Maryland and Carnegie Mellon University, in partnership with Facebook; 2020. *ArXiv Prepr ArXiv200914675*.
- The Lancet Infectious Diseases. COVID-19 vaccine equity and booster doses. *Lancet Infect Dis* 2021;21:1193. [https://doi.org/10.1016/S1473-3099\(21\)00486-2](https://doi.org/10.1016/S1473-3099(21)00486-2).
- Ministerio de Salud del Gobierno de Chile. Cuarta dosis de vacuna contra Sars-Cov-2: Personas inmunocomprometidas [cited 3 jul 2022]. Available at, <https://www.minsal.cl/wp-content/uploads/2022/01/Cuarta-dosis-de-vacuna-contra-SARS-CoV-2-Personas-Inmunocomprometidas.pdf>; 2022.
- Ministerio de Salud del Estado Peruano. Protocolo de aplicación de tercera y cuarta dosis para la vacunación contra la COVID-19 [cited 3 jul 2022]. Available at, <http://cdn.www.gob.pe/uploads/document/file/2987015/PROTOCOLO%203ERA%20Y%204TA%20DOSIS.pdf>; 2022.
- Ministerio de Salud del Estado Peruano. Protocolo de Aplicación de Dosis de Refuerzo de la Vacuna Contra la Covid-19 para personas de 60 años a más [cited 3 jul 2022]. Available at, <https://cdn.www.gob.pe/uploads/document/file/2332692/Protocolo.pdf>; 2021.
- Ministerio de Salud del Gobierno de Chile. Dosis de refuerzo en la campaña de vacunación contra Sars-Cov-2 en Chile [cited 3 jul 2022]. Available at, <https://www.minsal.cl/wp-content/uploads/2022/01/Dosis-de-Refuerzo-en-la-Campana-CC%83a-de-Vacunacio%CC%81n-contra-SARS-CoV-2-Fase-3-Nin%CC%83os-Nin%CC%83as-y-Adolescentes-NNA-2.pdf>; 2021.
- Carlton CN, García KM, Andino MV, Ollendick TH, Richey JA. Social anxiety disorder is Associated with Vaccination attitude, stress, and coping responses during COVID-19. *Cognit Ther Res* 2022. <https://doi.org/10.1007/S10608-022-10310-3>.
- Hao F, Wang B, Tan W, Husain SF, McIntyre RS, Tang X, et al. Attitudes toward COVID-19 vaccination and willingness to pay: comparison of people with and without mental disorders in China. *BJPsych Open* 2021;7. <https://doi.org/10.1192/BJO.2021.979>.
- Ministerio de Salud del Gobierno de Chile. Covid-19 en Chile en la Pandemia 2020-2022 [cited 3 jul 2022]. Available at, [https://www.minsal.cl/wp-content/uploads/2022/03/2022.03.03\\_LIBRO-COVID-19-EN-CHILE-1-1.pdf](https://www.minsal.cl/wp-content/uploads/2022/03/2022.03.03_LIBRO-COVID-19-EN-CHILE-1-1.pdf); 2022.
- Perlis RH, Ognyanova K, Santillana M, Lin J, Druckman J, Lazer D, et al. Association of major depressive symptoms with endorsement of COVID-19 vaccine misinformation among US adults. *JAMA Netw Open* 2022;5. <https://doi.org/10.1001/JAMANETWORKOPEN.2021.45697>. e2145697–e2145697.
- Haktanir A, Can N, Seki T, Kurnaz MF, Dilmaç B. Do we experience pandemic fatigue? current state, predictors, and prevention. *Curr Psychol* 2021;1–12. <https://doi.org/10.1007/s12144-021-02397-w>.
- Meacci L, Primicerio M. Pandemic fatigue impact on COVID-19 spread: a mathematical modelling answer to the Italian scenario. *Results Phys* 2021;31:104895. <https://doi.org/10.1016/j.rinp.2021.104895>.
- Tentolouris A, Ntanasis-Stathopoulos I, Vlachakis PK, Tsilimigras DI, Gavriatopoulou M, Dimopoulos MA. COVID-19: time to flatten the infodemic curve. *Clin Exp Med* 2021;21:161–5. <https://doi.org/10.1007/s10238-020-00680-x>.
- García-Saisó S, Martí M, Brooks I, Curioso WH, González D, Malek V, et al. The COVID-19 infodemic. <https://doi.org/10.26633/RPSP.2021.56>; 2021. 45:e56.
- Zintel S, Flock C, Arbogast AL, Forster A, von Wagner C, Sieverding M. Gender differences in the intention to get vaccinated against COVID-19: a systematic review and meta-analysis. *J Public Health* 2022;1–25. <https://doi.org/10.1007/s10389-021-01677-w>.
- Peretti-Watel P, Seror V, Cortaredona S, Launay O, Raude J, Verger P, et al. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. *Lancet Infect Dis* 2020;20:769–70. [https://doi.org/10.1016/S1473-3099\(20\)30426-6](https://doi.org/10.1016/S1473-3099(20)30426-6).
- Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. *Hum Vaccines Immunother* 2020;16:2204–14. <https://doi.org/10.1080/21645515.2020.1790279>.
- Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other Arab countries. *Vaccines* 2021;9:42. <https://doi.org/10.3390/vaccines9010042>.
- Organización de las Naciones Unidas. Covid-19 y liderazgo de las mujeres: Para responder con eficacia y reconstruir mejor [cited 3 jul 2022]. Available at, <https://www.unwomen.org/es/digital-library/publications/2020/06/policy-brief-covid-19-and-womens-leadership>; 2020.
- Martínez-García M, Rabasa A, Barber X, Polotskaya K, Roomp K, Oliver N. Key factors affecting people's unwillingness to be confined during the COVID-19 pandemic in Spain: a large-scale population study. *Sci Rep* 2021;11:1–18. <https://doi.org/10.1038/s41598-021-97645-1>.
- Jacques-Aviñó C, López-Jiménez T, Medina-Perucha L, de Bont J, Berenguera A. Social conditions and mental health during COVID-19 lockdown among people



who do not identify with the man/woman binomial in Spain. PLoS One 2021;16: e0256261. <https://doi.org/10.1371/journal.pone.0256261>.